Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations

  • Rozita Tamjidifar
  • Morteza Akbari
  • Saeed Tarzi
  • Mahsa Sadeghzadeh
  • Mahsa Abolghasemi
  • Elham Poursaei
  • Navid Shomali
  • Farshad MahdaviEmail author
Original Research



One of the most common cancers in the world is colorectal cancer, which has increased significantly in recent decades. In the carcinogenicity process in the colon, there are genes involved in various cellular processes, such as cell cycle, apoptosis, and cell migration. According to studies carried out, both miR-506 and SPON 1 genes are involved in the process which initiates and promotes cancer. In this study, alterations in the expression of target genes from the viewpoint of carcinogenicity were studied and evaluated.


Fifty tumor tissues and normal marginal tissue were collected from patients who were undergoing colorectal cancer surgery. After the extraction of RNA, the real-time PCR method was performed to evaluate the gene expression. Also, alterations of gene expression in response to defined amounts of chemotherapeutic drugs (IC50) were evaluated. P < 0.05 was considered statistically significant.


The relative expression level of miR-506 in tumor tissues was significantly decreased in comparison with healthy marginal tissues (P = 0.044). On the other hand, the SPON1 gene expression level was decreased too in tumor tissues in comparison with healthy marginal tissues (P = 0.019). There was also a significant relationship between the expression of target genes and clinicopathological involvement. However, there was no significant alteration in these genes along with the chemotherapeutic drug.


These findings suggest that the relative expression of miR-506 and SPON 1 gene can be considered as a diagnostic or predictive biomarker for colorectal cancer. However, further studies on protein levels should be conducted.


CRC miR-506 SPON1 Diagnosis Prognosis Treatment 



This study was carried out and supported at the Immunology Research Center, Tabriz University of Medical Science, Tabriz, Iran.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kuipers EJ, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065.CrossRefGoogle Scholar
  2. 2.
    Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–29.CrossRefGoogle Scholar
  3. 3.
    Morris EJ, Penegar S, Whitehouse LE, Quirke P, Finan P, Bishop DT, et al. A retrospective observational study of the relationship between family history and survival from colorectal cancer. Br J Cancer. 2013;108(7):1502–7.CrossRefGoogle Scholar
  4. 4.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8.CrossRefGoogle Scholar
  5. 5.
    Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–47.CrossRefGoogle Scholar
  6. 6.
    Shomali, N., et al., Downregulation of miR-146a promotes cell migration in Helicobacter pylori-negative gastric cancer. 2019. 120(6): p. 9495–9505.Google Scholar
  7. 7.
    Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: new outlooks. Biomed Pharmacother. 2018;97:1319–30.CrossRefGoogle Scholar
  8. 8.
    Ghasabi M. et al. MicroRNAs in cancer drug resistance: basic evidence and clinical applications. 2019;234(3):2152–68.Google Scholar
  9. 9.
    Fadaka AO, Pretorius A, Klein A. Biomarkers for stratification in colorectal cancer: MicroRNAs. Cancer Control. 2019;26(1):1073274819862784.CrossRefGoogle Scholar
  10. 10.
    Chen B, Xia Z, Deng YN, Yang Y, Zhang P, Zhu H, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 2019;9(1):180212.CrossRefGoogle Scholar
  11. 11.
    Dong Y, Yu J, Ng SS. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res. 2014;6:405–22.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Chen Z, et al. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget. 2015;6(35):38139–50.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Li J, Ju J, Ni B, Wang H. The emerging role of miR-506 in cancer. Oncotarget. 2016;7(38):62778–88.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM, Xiao SD, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585(22):3560–8.CrossRefGoogle Scholar
  15. 15.
    Chang H, et al. Spondin 1 promotes metastatic progression through Fak and Src dependent pathway in human osteosarcoma. Biochem Biophys Res Commun. 2015;464(1):45–50.CrossRefGoogle Scholar
  16. 16.
    Dai W, Huang HL, Hu M, Wang SJ, He HJ, Chen NP, et al. microRNA-506 regulates proliferation, migration and invasion in hepatocellular carcinoma by targeting F-spondin 1 (SPON1). Am J Cancer Res. 2015;5(9):2697–707.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Akbari M, et al. CD133: an emerging prognostic factor and therapeutic target in colorectal cancer. Cell Biol Int. 2019.Google Scholar
  18. 18.
    Karimi, L., et al., miRNA-143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro. 2019. 234(11): p. 21359–21368.Google Scholar
  19. 19.
    Shanehbandi, D.Google Scholar
  20. 20.
    Noorolyai, S., et al., The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer. 2019. 234(5): p. 5664–5673.Google Scholar
  21. 21.
    Vasile L, Olaru A, Munteanu M, Pleşea IE, Surlin V, Tudoraşcu C. Prognosis of colorectal cancer: clinical, pathological and therapeutic correlation. Romanian J Morphol Embryol. 2012;53(2):383–91.Google Scholar
  22. 22.
    Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2013;32(1):21–30.CrossRefGoogle Scholar
  23. 23.
    Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1–2):29–39.CrossRefGoogle Scholar
  24. 24.
    Wang F, Ma Y, Wang H, Qin H. Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer. Oncol Lett. 2017;13(3):1048–57.CrossRefGoogle Scholar
  25. 25.
    Lu Z, Zhang W, Gao S, Jiang Q, Xiao Z, Ye L, et al. MiR-506 suppresses liver cancer angiogenesis through targeting sphingosine kinase 1 (SPHK1) mRNA. Biochem Biophys Res Commun. 2015;468(1–2):8–13.CrossRefGoogle Scholar
  26. 26.
    Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56(2):687–97.CrossRefGoogle Scholar
  27. 27.
    Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–36.CrossRefGoogle Scholar
  28. 28.
    Ben Mousa A. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14(1):40–2.CrossRefGoogle Scholar
  29. 29.
    Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, et al. The role of microRNAs in hepatocellular carcinoma. J Cancer. 2018;9(19):3557–69.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Rozita Tamjidifar
    • 1
    • 2
  • Morteza Akbari
    • 1
  • Saeed Tarzi
    • 1
    • 2
  • Mahsa Sadeghzadeh
    • 3
  • Mahsa Abolghasemi
    • 3
  • Elham Poursaei
    • 3
  • Navid Shomali
    • 1
    • 4
  • Farshad Mahdavi
    • 5
    • 6
    Email author
  1. 1.Immunology Research CenterTabriz University of Medical SciencesTabrizIran
  2. 2.Department of Biology Ahar BranchIslamic Azad UniversityAharIran
  3. 3.Tuberculosis and Lung Disease Research CenterTabriz University of Medical SciencesTabrizIran
  4. 4.Student Research CommitteeTabriz University of Medical SciencesTabrizIran
  5. 5.Drug Applied Research CenterTabriz University of Medical SciencesTabrizIran
  6. 6.Department of General SurgeryTabriz University of Medical SciencesTabrizIran

Personalised recommendations